Blue Notes
Immune-mediated inflammatory disorders (IMIDs) including inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis/psoriatic arthritis (PSO), and ankylosing spondylitis (AS), are associated with increased risk of major adverse cardiovascular events (MACE). There is uncertainty regarding the cardiovascular safety of newer medications for IMIDs such as biologics and small molecules (anti-IL-23, anti-IL-12/23, anti-TNFs, and JAKi). This network meta-analysis pooled 40 studies (36 RCTs) that reported MACE (myocardial infarction, cerebrovascular accident, unstable angina, cardiovascular death, or heart failure) in ...
Source: Clinical Gastroenterology and Hepatology - April 23, 2024 Category: Gastroenterology Authors: Charles J. Kahi Tags: Blue Notes Source Type: research
GSE262954 Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis
Conclusions: Secukinumab appears to be an effective treatment for PRP and warrants further investigation. PRP is a tra nscriptionally heterogeneous disease, reflecting its variable response to therapy. Agents targeting other IL-17 isoforms and innate immune mediators should be considered for future clinical trials. What is already known about this topic? The pathogenesis of pityriasis rubra pilaris is incompletely u nderstood. Successful treatment has been reported with a variety of immunomodulatory agents, but disease is often refractory to therapy. Interleukin (IL)-17 is thought to drive keratinocyte proliferation and va...
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Adherence, persistence and treatment switching in psoriasis
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - April 23, 2024 Category: Allergy & Immunology Authors: Fiorenzo Santoleri Felice Musicco Chiara Fulgenzio Paolo Abrate Laura Pestrin Enrico Pasut Germana Modesti Romina Giannini Stefania De Rosa Mariantonietta Piccoli Grazia Mingolla Eva Zuzolo Pietro Gazzola Martina Roperti Gabriella Pieri Valentina Montreso Source Type: research
Serum Beta-Defensin-2 is a biomarker for psoriasis but not subclinical atherosclerosis: Role of IL17a, PI-3 kinase and Rac1
CONCLUSIONS: Our findings expand on the potential role of BD2 as a tractable biomarker in psoriasis patients and describes the role of an IL-17A-PI3-kinase/Rac signaling axis in regulating BD2 levels in keratinocytes.PMID:38646149 | PMC:PMC11031204 | DOI:10.1002/jvc2.278 (Source: Atherosclerosis)
Source: Atherosclerosis - April 22, 2024 Category: Cardiology Authors: C J Pantoja H Li J Rodante A Keel A V Sorokin A Svedbom H L Teague M Stahle N N Mehta M P Playford Source Type: research
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
ConclusionsContinued treatment with ixekizumab provided long-term sustained scalp clearance over 5 years to patients with moderate-to-severe plaque psoriasis and baseline scalp involvement, and holistic improvements occurred across clinical outcomes, patient-reported outcomes, and quality of life.Clinical Trial NumbersNCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 22, 2024 Category: Dermatology Source Type: research
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO
ConclusionThis real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month 6 in the anti-IL-17A cohort compared to the other biologics cohort. Of the individual biologics studied, ixekizumab showed the highest numerical improvements in nail psoriasis at month 12.Trial registrationEUPAS24207. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - April 22, 2024 Category: Dermatology Source Type: research
GSE231728 Celastrol targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression
Conclusion: We report that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages. The use of celastrol maybe a noveltherapeuticoption for psoriasis. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 20, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
The Immunology of Psoriasis —Current Concepts in Pathogenesis
AbstractPsoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the pathogenesis of psoriasis. Emerging evidence indicates that dendritic cells, TH17 cells, and keratinocytes constitute a pathogenic triad in psoriasis. Dendritic cells produce TNF- α and IL-23 to promote T cell differentiation toward TH17 cells that produce key psoriatic cytokines IL-17, IFN- γ, and IL-22. Their activity results in skin inflammation and activation and hype...
Source: Clinical Reviews in Allergy and Immunology - April 20, 2024 Category: Allergy & Immunology Source Type: research
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - April 20, 2024 Category: Dermatology Authors: Alexander Rimke, Siddhartha Sood, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Lauren A. Stark, Ronald Vender, Jensen Yeung, Vimal H. Prajapati Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Dermato-Venereologica - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Derm Venereol A... - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Dermato-Venereologica - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis. 2024 Apr 17. doi: 10.1089/derm.2023.0292. Online ahead of print.ABSTRACT Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ke...
Source: Dermatitis - April 18, 2024 Category: Dermatology Authors: Syed Minhaj Rahman Yousef Salem Aamir Hussain Source Type: research
